Krystal Biotech, Inc. (KRYS) Q2 2024 Earnings
KRYS·Reported August 5, 2024·Before market open
Krystal Biotech, Inc. reported Q2 2024 revenue of $70.3M, beat analyst consensus of $65.3M by $5.0M. Diluted EPS came in at $0.86, beat the $0.50 consensus by $0.36.
Revenue
$70.3Mbeat by $5.0M
Consensus: $65.3MDiluted EPS
$0.86beat by $0.36
Consensus: $0.50
Financial Snapshot
Trailing eight quarters through Q2 2024
Q2 2024 Earnings FAQ
Common questions about Krystal Biotech, Inc.'s Q2 2024 earnings report.
Krystal Biotech, Inc. (KRYS) reported Q2 2024 earnings on August 5, 2024 before market open.
Krystal Biotech, Inc. reported revenue of $70.3M and diluted EPS of $0.86 for Q2 2024.
Revenue beat the consensus estimate of $65.3M by $5.0M. EPS beat the consensus estimate of $0.50 by $0.36.
You can read the 10-Q periodic report (0001711279-24-000040) directly on SEC EDGAR. The filing index links above go to sec.gov.